Stock analysis · NYSE: SGI · Consumer discretionary

Somnigroup (SGI) Stock Analysis: Growth Quality Under Pressure

Acquisitions lift reported sales, but weaker legacy demand and a generous leverage denominator complicate the recovery case.

Edition: . Market data: November 20, 2026 close. Financials: quarter and nine months ended September 30, 2026; released and filed November 9. All dollar amounts are U.S. dollars.

Executive assessment: a recovery to verify, not assume

Somnigroup ended November 20 at $57.82, below both its 14-period Kaufman adaptive moving average and 50-session simple moving average. The price weakness sits alongside a genuine operating tension: third-quarter sales rose 10.8%, yet the newly acquired Leggett & Platt contributed more revenue than the entire year-over-year increase. Meanwhile, adjusted earnings improved while GAAP earnings fell. The central question is not whether the business has grown larger, but whether its existing operations can recover without relying on acquisition accounting, temporary benefits or unrealized synergies. [1] [2]

November 20 close

$57.82

Down 10.1% from August 24, the first session in the 90-calendar-day window.

2026 adjusted EPS guidance

$2.85–$2.95

Price implies 19.6–20.3 times management's non-GAAP outlook.

Credit-facility leverage

2.69×

Includes pre-acquisition earnings and future synergy allowances in the denominator.

Assessment: a conditional watchlist candidate rather than a technically confirmed recovery. Cash generation supports the investment case, but neither a falling share price nor a near-20-times adjusted earnings multiple establishes a margin of safety. These observations are analysis, not a personalized recommendation. [3]

The business: brands, stores and components

Somnigroup International is the former Tempur Sealy, not the former Silicon Graphics business associated with the historical SGI ticker. It combines Tempur-Pedic, Sealy and Stearns & Foster brands with Mattress Firm and Dreams retail operations. Leggett & Platt, acquired on August 26, 2026, adds bedding and furniture components alongside specialized engineered products. The resulting business spans manufacturing, wholesale distribution and direct retail. [2] [4]

That breadth can improve purchasing, distribution and product development, but it does not eliminate consumer cyclicality. Mattresses are postponable purchases, and retail financing costs can affect conversion and profitability. Vertical integration also makes reported segment revenue and consolidated growth harder to interpret: intersegment sales are eliminated, and a partial quarter of a new subsidiary is not a like-for-like demand recovery. The filing describes a bedding industry still under pressure in 2026. [3]

Fundamentals: the growth bridge matters more than the headline

Quarter ended September 30; amounts in USD millions except diluted EPS. Source: November 9 company release. Adjusted measures are non-GAAP. [2]
MetricQ3 2026Q3 2025Interpretation
Net sales2,350.82,122.6+10.8%; includes 372.6 from Leggett & Platt
GAAP operating income297.4314.7−5.5%
Adjusted operating income364.2343.7+6.0%
GAAP diluted EPS$0.74$0.83−10.8%
Adjusted diluted EPS$1.04$0.95+9.5%
GAAP gross margin42.0%44.9%−290 basis points

The arithmetic is revealing. Subtracting the acquired stub-period revenue from consolidated sales gives $1,978.2 million, 6.8% below the prior-year consolidated total. This is a simple acquisition-excluded comparison, not a company-reported organic or constant-currency growth measure. Nevertheless, it demonstrates why 10.8% reported growth cannot be treated as evidence of strengthening underlying demand. [2]

The operating detail points in the same direction. Mattress Firm sales fell 5.8% to $1,008.3 million; Tempur Sealy North America sales fell 5.8% to $693.1 million; and International sales declined 12.3% to $276.8 million. Dreams sales dropped 34.7% after an ERP implementation caused operational disruption. Recovery there is an execution opportunity, but also a reminder that integration and technology spending can destroy near-term sales rather than merely add costs. [3]

Margin quality requires equal care. North America GAAP gross margin improved to 64.7% from 58.4%. The filing attributes approximately $20 million, or 300 basis points, to tariff refunds, alongside acquisition synergies and mix, partly offset by inflation. Investors should not extrapolate that refund benefit as a recurring quarterly run rate. Consolidated adjusted net income of $228.9 million exceeded GAAP net income of $163.5 million by $65.4 million; the reconciliation includes transaction costs, business-combination charges, debt-extinguishment costs and purchase-accounting effects, net of tax adjustments. Non-GAAP earnings help isolate management's operating view, but do not make those economic costs disappear. [3] [2]

Cash and leverage: stronger liquidity, qualified comfort

For the nine months ended September 30, operating cash flow was $831.9 million and purchases of property, plant and equipment were $174.3 million. Their difference, $657.6 million, is a simple cash-flow-after-capex calculation—not cash available entirely for shareholders after acquisitions, financing and dividends. It nevertheless provides a more tangible counterweight to weak sales than adjusted EPS alone. [3]

At September 30, consolidated indebtedness was $5,627.0 million and netted cash was $612.1 million, leaving $5,014.9 million under the credit-facility net-debt definition. Reported balance-sheet debt, net of deferred financing costs, was $5,381.6 million; the $245.4 million financing-cost addback explains the difference. These are distinct debt presentations, not interchangeable totals. [2]

The widely quoted 2.69-times leverage ratio uses $1,864.8 million of adjusted EBITDA per the credit facility. That denominator includes $330.5 million of Leggett & Platt earnings before acquisition and $145 million of future cost synergies across the two acquisitions. Dividing the same $5,014.9 million net-debt numerator by the separately disclosed $1,389.3 million trailing adjusted EBITDA gives approximately 3.61 times. This alternative is not the covenant ratio or a fully comparable pro-forma ratio; it illustrates sensitivity to the denominator. The 2.69-times figure is a useful covenant measure, not proof that all credited synergies have become cash earnings. [3]

Technicals: price has not confirmed the recovery

The requested August 22–November 20 window contains 64 observed trading sessions, beginning Monday, August 24. November 21 is the Saturday editorial date, not a price observation. SGI fell 4.8% from the November 13 close of $60.76 to $57.82 on November 20. A rebound to $62.45 on November 18 did not hold. None of this establishes the cause of the selling or identifies the sellers. [1]

Daily closing observations in USD; no weekend values or gap-filling. KAMA (14) and SMA (50) use preceding 2026 history for initialization; only the requested 90-calendar-day window is displayed. KAMA is adaptive and its value depends on initialization history. Source: dated price and indicator series. [1]

November 20 technical reference levels; descriptive, not price targets. [1]
MeasureUSDClose relative to reference
Close57.82Lowest closing value in the displayed window
KAMA (14)64.109.8% below
SMA (50)63.248.6% below

With price below both averages, the current configuration favors caution over a claim of established upward momentum. Sustained closes back above those evolving averages would strengthen the technical case; a one-day bounce would not. Neither average is guaranteed support or resistance, and the window low does not define a downside floor.

Valuation and catalysts: what must earn the multiple

At $57.82, management's revised full-year adjusted EPS outlook of $2.85–$2.95 implies 19.6–20.3 times earnings, or 19.9 times the $2.90 midpoint. This is a price-to-guided-adjusted-EPS calculation, not a GAAP trailing P/E or a consensus estimate. The company did not reconcile its forward adjusted EPS outlook to GAAP EPS because it could not predict the necessary adjustments with reasonable certainty. No valuation target is assigned here. [2]

The next meaningful catalysts are evidence, not calendar promises: delivery and conversion normalization at Dreams; stabilization in Mattress Firm and North America sales; actual realization of acquisition savings; and cash generation that reduces debt without depending on denominator addbacks. The November 9 outlook and filing provide the baseline for testing those outcomes, not assurance that they will occur. Company announcements in November do not change that financial hurdle.

Conditional scenarios, not forecasts. No probabilities or unsupported price targets.
CaseEvidence requiredInvestment implication
RecoveryDreams disruption subsides; legacy sales stabilize; synergy savings appear in cash results.The adjusted earnings base becomes more credible; a sustained trend repair would add confirmation.
Uneven stabilizationCash generation continues but sales remain weak and adjustments persist.A near-20-times guided multiple still demands discipline; acquisition scale alone does not justify rerating.
Execution setbackDemand deteriorates, integration costs persist or credited savings fall short.Earnings and leverage assumptions weaken together; a lower price need not mean better value.

Risks and decision checklist

  • Demand and financing: postponable purchases and consumer credit costs can pressure volumes and retail margins.
  • Integration: Leggett & Platt and Mattress Firm introduce execution, accounting and channel complexity; Dreams illustrates operational disruption risk.
  • Earnings quality: non-GAAP exclusions and tariff refunds can make apparent margin strength less repeatable.
  • Balance sheet: covenant-defined leverage includes pre-acquisition earnings and future savings; cash interest and integration spending still require funding.
  • Market risk: the weakest close in the displayed window is a warning about current price behavior, not a signal that the decline must end. [3] [1]

Bottom line: prioritize underlying sales stabilization, narrower GAAP-to-adjusted gaps and realized cash savings. Somnigroup has valuable brands and substantial operating cash generation, but the reported growth rate overstates the evidence of demand recovery. Until those operating tests improve, the burden of proof remains with the recovery thesis.

Sources and measurement notes

  1. SGI dated daily closing series, August 22–November 20, 2026; KAMA (14) and SMA (50), initialized with history from January 2026. StockApp company tear sheet, last market date November 20. StockApp links may require authentication.
  2. Somnigroup: third-quarter results and revised outlook, issuer release distributed November 9, 2026. Includes non-GAAP reconciliations, acquisition timing and guidance. Financial statement amounts are USD millions unless per share.
  3. Somnigroup Form 10-Q, filed November 9, 2026, for September 30, 2026; accession 0001206264-26-000134. Filing statement tables expressed in thousands are converted to millions here; MD&A tables use millions.
  4. StockAnalysis company overview and financials, inspected November 21, 2026, for identity and financial context. Dated issuer statements govern the figures in this report rather than an undated rolling snapshot.

Price changes use closing values, not total returns. Financial comparisons are year-over-year unless stated otherwise. Financial statements are unaudited interim results. No Saturday trading bar, original Reddit discussion evidence, analyst consensus or probability-weighted valuation is implied. This report evaluates operating and market evidence, not individual suitability.